Objective: The treatment of nasolacrimal canal obstruction through endoscopic DCR is both e!ective and safe. Our
study aims to assess the preoperative factors in"uencing the success of endoscopic dacryocystorhinostomy.
Methods: We conducted a retrospective review of all consecutive endoscopic DCR procedures performed over a 5-year period from 2019 to 2024. All patients underwent a minimum 6-month follow-up after stent removal. Patient records were examined for demographic details, previous surgical procedures, reasons for failure, clinical and surgical characteristics, adjunctive procedures, and success rates at the #nal follow-up.
Results: Endoscopic dacryocystorhinostomy (eDCR) was performed on a total of 58 patients, with a mean follow-up period of 31.88 ± 15.79 months (range, 6-60). Upon further examination of comorbid disease subtypes, a statisti- cally signi#cant relationship was observed between the presence of autoimmune diseases (Hashimoto’s thyroiditis, Graves’ disease, ankylosing spondylitis, psoriasis) and the likelihood of undergoing revision surgery (P = .005). Of the revision endo-DCR group, 9 (75%) patients underwent concurrent endonasal surgery during their revision operation. Septoplasty was performed in 2 (16.6%) cases, and concha bullosa surgery was performed in 7 (58.4%) cases. A sta- tistically signi#cant di!erence was observed among the concurrent surgeries, particularly in terms of concha bullosa surgery (P = .001).
Conclusion: Understanding the factors correlated with endo-DCR failure can inform preoperative counseling and re#ne intraoperative surgical approaches for patients undergoing treatment for nasolacrimal canal obstruction.
Endoscopic dacryocystorhinostomy (DCR) failed DCR revision DCR long-term autoimmune disease smoking
| Primary Language | English |
|---|---|
| Subjects | Immunology (Other) |
| Journal Section | Research Article |
| Authors | |
| Submission Date | August 3, 2024 |
| Acceptance Date | October 7, 2024 |
| Publication Date | April 20, 2025 |
| Published in Issue | Year 2025 Volume: 8 Issue: 1 |
You can find the current version of the Instructions to Authors at: https://www.eurjrhinol.org/en/instructions-to-authors-104
Starting on 2020, all content published in the journal is licensed under the Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International
License which allows third parties to use the content for non-commercial purposes as long as they give credit to the original work. This license
allows for the content to be shared and adapted for non-commercial purposes, promoting the dissemination and use of the research published in
the journal.
The content published before 2020 was licensed under a traditional copyright, but the archive is still available for free access.